TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26794937

Group type: EXPERIMENTAL
Intervention: Convers Plus 4/1.25 mg Tablet (test)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bipreterax 4/1.25 mg Tablet (reference)
Number of subjects: 24
Study: 25886226

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.075 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Granisetron (2 mg)
Number of subjects: 120
Study: 22777579

Group type: EXPERIMENTAL
Intervention: Didactic teaching
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electronic learning
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (baseline)
Number of subjects: 20
Study: 20478332

Group type: EXPERIMENTAL
Intervention: Community-based prevention activities (intervention)
Number of subjects: 5024

Group type: COMPARATOR
Intervention: Control communities (non-intervention)
Number of subjects: 5024
Study: 17080003

Group type: EXPERIMENTAL
Intervention: Salmeterol (100 microg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: LPS (100 microg)
Number of subjects: 32
Study: 16227761

Group type: EXPERIMENTAL
Intervention: Telmisartan 40-80 mg daily plus hydrochlorothiazide 12.5 mg daily (if needed)
Number of subjects: 1469
Study: 11953670

Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy (epoetin-alpha)
Number of subjects: 0
Study: 10441604

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 59

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combined treatment (Phenobarbital first)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combined treatment (Phenytoin first)
Number of subjects: 59
Study: 7476282

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-fat diet (LCD)
Number of subjects: 10
Study: 2181334

Group type: EXPERIMENTAL
Intervention: Nimodipine 2 mg/h
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Nimodipine 3 mg/h
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Nimodipine (both doses) in patients with Hunt and Hess grades IV or V
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Nimodipine (both doses) in patients with Hunt and Hess grades I to III
Number of subjects: 204
Study: 473853

Group type: EXPERIMENTAL
Intervention: 200 mg Metoprolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15 mg Pindolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study: 30536405

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (1.8 mg m-2 per cycle)
Number of subjects: 250
Study: 27864127

Group type: EXPERIMENTAL
Intervention: latiglutenase 100, 300, 450, 600, or 900 mg daily for 12 or 24 weeks
Number of subjects: 494

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 494
Study: 24983679

Group type: EXPERIMENTAL
Intervention: Doula support
Number of subjects: 214

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 214
Study: 23347994

Group type: EXPERIMENTAL
Intervention: Variable power (VAR) cycling at 65% MAP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Constant power (CON) cycling at 65% MAP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control 9.3‐km run with no preceding exercise
Number of subjects: 12
Study: 21280267

Group type: EXPERIMENTAL
Intervention: Fexofenadine with water
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fexofenadine with apple juice
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Midazolam with apple juice
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fexofenadine uptake by OATP2B1 cRNA‐injected oocytes
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Apple juice effect on fexofenadine uptake
Number of subjects: 14
Study: 19853699

Group type: EXPERIMENTAL
Intervention: Rate control with heart rate >=80 beat/min
Number of subjects: 522

Group type: COMPARATOR
Intervention: Rate control with heart rate <80 beat/min
Number of subjects: 522
Study: 16503582

Group type: EXPERIMENTAL
Intervention: Surface lidocaine anesthesia
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Larger pressure probes (1.6 and 15 mm)
Number of subjects: 34
Study: 12467956

Group type: EXPERIMENTAL
Intervention: Sucrose solution swallowed (0, 5, 10, 20, and 40%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sucrose solution spit (0, 5, 10, 20, and 40%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fear to swallow sucrose solution (covariate)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Drive for Thinness (covariate)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Social Anhedonia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physical Anhedonia
Number of subjects: 60
Study: 10635540

Group type: EXPERIMENTAL
Intervention: ECHO beverage (Drink 1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ECHO beverage (Drink 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Commercially available drinks (Drink 3)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Water (Drink 4)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Commercially available drinks (Drink 5)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ECHO beverage
Number of subjects: 16
Study: 11327791

Group type: EXPERIMENTAL
Intervention: Posteroanterior central vertebral pressure (PA mobilisation)
Number of subjects: 18
Study: 2206140

Group type: EXPERIMENTAL
Intervention: Fish oil supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alpha‐tocopherol‐enriched coconut oil supplements (placebo)
Number of subjects: 0
Study: 7227621

Group type: EXPERIMENTAL
Intervention: Prothiaden (75 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Lentizol (50 mg)
Number of subjects: 50
Study: 30385886

Group type: EXPERIMENTAL
Intervention: Genetic counseling and testing among White/Other YBCS
Number of subjects: 883

Group type: COMPARATOR
Intervention: Barriers to access genetic services
Number of subjects: 883

Group type: COMPARATOR
Intervention: Factors negatively associated with use of genetic services
Number of subjects: 883

Group type: COMPARATOR
Intervention: Knowledge of breast cancer risk factors
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Higher education and genetic counseling
Number of subjects: 883
Study: 29314065

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) with open-flap debridement (OFD)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PRF + porous hydroxyapatite (HA) with OFD
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (OFD alone)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) with OFD
Number of subjects: 90
Study: 25953494

Group type: EXPERIMENTAL
Intervention: Shock wave therapy (ESWT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nutraceutical composed of alpha lipoic acid (ALA), conjugated linoleic acid (GLA), and Echinacea angustifolia
Number of subjects: 60
Study: 23433822

Group type: EXPERIMENTAL
Intervention: Prize-based abstinence incentive intervention
Number of subjects: 415

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 415
Study: 20833820

Group type: EXPERIMENTAL
Intervention: Quality-improvement intervention targeting clinicians with five components: clinician education, local champions, academic detailing, clinician feedback of quality data, and system supports.
Number of subjects: 2318
Study: 19812443

Group type: EXPERIMENTAL
Intervention: alpha-GalCer 0.1 microg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: alpha-GalCer 1 microg/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: alpha-GalCer 10 microg/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 16802067

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT) with a belly board
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intensity-modulated radiotherapy (IMRT) without a belly board
Number of subjects: 20
Study: 16081625

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12237187

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 0
Study: 10075098

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 7
Study: 7553070

Group type: EXPERIMENTAL
Intervention: injections of allergen-specific antibody complexes
Number of subjects: 19
Study: 2187982

Group type: EXPERIMENTAL
Intervention: Exercise plus relaxation and breathing therapy (Treatment A)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Exercise training only (Treatment B)
Number of subjects: 156
Study: 7315768

Group type: EXPERIMENTAL
Intervention: Repletion diet (depletion diet plus 200 micrograms Se/day as high-Se wheat or wheat plus tuna fish)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Depletion diet (33 to 36 micrograms Se/day)
Number of subjects: 6
Study: 31498113

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after one-month dual antiplatelet therapy (DAPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-month DAPT followed by 12-month aspirin monotherapy (control)
Number of subjects: 0
Study: 31071483

Group type: EXPERIMENTAL
Intervention: Imaginal retraining
Number of subjects: 84

Group type: COMPARATOR
Intervention: Wait-list control group (care-as-usual)
Number of subjects: 84
Study: 28322366

Group type: EXPERIMENTAL
Intervention: Xyliwhite toothpaste (xylitol)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Periobiotic toothpaste (xylitol-probiotic)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Colgate Max Fresh toothpaste (fluoride)
Number of subjects: 48
Study: 27583931

Group type: EXPERIMENTAL
Intervention: Balanced anesthesia (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Balanced anesthesia with hypertension (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (Group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with hypertension (Group D)
Number of subjects: 80
Study: 23823329

Group type: EXPERIMENTAL
Intervention: Diet-Exercise Group
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Diet Group
Number of subjects: 107

Group type: COMPARATOR
Intervention: Exercise Group
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 107
Study: 23225838

Group type: EXPERIMENTAL
Intervention: Carbamazepine (100 mg, 3 times a day for 60 days) + Botulinum toxin A (local intramuscular injections)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Botulinum toxin A (local intramuscular injections only)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Carbamazepine + Botulinum toxin A
Number of subjects: 58

Group type: COMPARATOR
Intervention: Botulinum toxin A
Number of subjects: 58
Study: 19229454

Group type: EXPERIMENTAL
Intervention: Home exercise video programme (n=10), advised to follow 4 times a week for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chronic obstructive pulmonary disease educational booklet only (n=10)
Number of subjects: 20
Study: 17449945

Group type: EXPERIMENTAL
Intervention: Coflex (Spine motion, Germany)
Number of subjects: 42

Group type: COMPARATOR
Intervention: PLIF
Number of subjects: 42
Study: 15023158

Group type: EXPERIMENTAL
Intervention: Quantitative plasma viral load measurements
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Routine monitoring of CMV plasma viral load
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Single time point measures at the end of prophylaxis or month 4
Number of subjects: 364
Study: 12185405

Group type: EXPERIMENTAL
Intervention: 15 mg mirtazapine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 9832077

Group type: EXPERIMENTAL
Intervention: Dietary lycopene supplementation (tomato juice, spaghetti sauce, tomato oleoresin) for 1 week each
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dietary lycopene supplementation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 19
Study: 7857508

Group type: EXPERIMENTAL
Intervention: hypericum extract
Number of subjects: 24

Group type: COMPARATOR
Intervention: maprotiline
Number of subjects: 24
Study: 2562333

Group type: EXPERIMENTAL
Intervention: Omeprazole (10 mg or 20 mg each morning for 2 weeks)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily for 2 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ranitidine (150 mg nightly for 1 year)
Number of subjects: 9
Study: 1179368

Group type: EXPERIMENTAL
Intervention: DTIC and vincristine (VCR) in 3 day courses repeated every 4‐5 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: DTIC, VCR and chloroethyl cyclohexyl nitrosourea in 3 day courses repeated every 6‐7 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with chemotherapy
Number of subjects: 42
Study: 29858027

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg/day)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2) and Bevacizumab (7.5 mg/kg) every 21 days
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 147

Group type: COMPARATOR
Intervention: Docetaxel-bevacizumab
Number of subjects: 147
Study: 27250219

Group type: EXPERIMENTAL
Intervention: Beauty care program (two training sessions per month for 3 months and daily facial skin care)
Number of subjects: 871

Group type: COMPARATOR
Intervention: Control group (comprehensive geriatric assessment)
Number of subjects: 871
Study: 24184299

Group type: EXPERIMENTAL
Intervention: Synbiotic supplement for eight weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo for eight weeks
Number of subjects: 70
Study: 21452176

Group type: EXPERIMENTAL
Intervention: Paroxetine (40 mg/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 49
Study: 20170345

Group type: EXPERIMENTAL
Intervention: Laparoscopic endometrioma stripping surgery
Number of subjects: 47

Group type: COMPARATOR
Intervention: Normo-ovulatory control cases
Number of subjects: 47
Study: 18520184

Group type: EXPERIMENTAL
Intervention: Endolymphatic sac drainage and steroid instillation (G-I)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Endolymphatic sac drainage without steroid instillation (G-II)
Number of subjects: 197

Group type: COMPARATOR
Intervention: No treatment (G-III)
Number of subjects: 197
Study: 15921829

Group type: EXPERIMENTAL
Intervention: MC-4 vaccine
Number of subjects: 100
Study: 12570111

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 750
Study: 10725767

Group type: EXPERIMENTAL
Intervention: DHA supplement (200 mg DHA/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: (13)C-labeled linoleic acid (1 mg/kg body weight)
Number of subjects: 10
Study: 8542857

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with bupivacaine-adrenaline before starting surgery and a booster dose after 60 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural dose of bupivacaine-adrenaline at 60 min
Number of subjects: 20
Study: 1781803

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg with glycine 250 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 500 mg without glycine
Number of subjects: 20
Study: 6168829

Group type: EXPERIMENTAL
Intervention: Prenalterol (0.1, 0.25, and 0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prenalterol (10 times higher dose after beta-blockers)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol (20 mg)
Number of subjects: 0
Study: 30159664

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 180

Group type: COMPARATOR
Intervention: Loss-framed message
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Message elaboration
Number of subjects: 180
Study: 27125661

Group type: EXPERIMENTAL
Intervention: Social condition (e-cigarette ads focused on social enhancement)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Health condition (e-cigarette ads focused on harm-reduction)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Social condition
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control condition (ads of everyday objects only)
Number of subjects: 187
Study: 23544435

Group type: EXPERIMENTAL
Intervention: 1-h exposure to second-hand smoke (SHS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal room air (control)
Number of subjects: 19
Study: 22192847

Group type: EXPERIMENTAL
Intervention: MF59-H5N1 vaccine
Number of subjects: 3647
Study: 20210562

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy (SAPT)
Number of subjects: 495

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 495
Study: 18984887

Group type: EXPERIMENTAL
Intervention: 12-week buprenorphine-naloxone (up to 24 mg per day for 9 weeks, then tapered to week 12)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Detox group (14-day taper, up to 14 mg per day)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 12-week buprenorphine-naloxone
Number of subjects: 152

Group type: COMPARATOR
Intervention: Detox group
Number of subjects: 152
Study: 15974485

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Gui‐zhi‐fu‐ling‐wan (herbal therapy)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Control group (women without hot flashes)
Number of subjects: 352
Study: 12098350

Group type: EXPERIMENTAL
Intervention: Case conferencing initiated by specialist services and arranged flexibly
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional case conferencing
Number of subjects: 29
Study: 11029568

Group type: EXPERIMENTAL
Intervention: bupivacaine-clonidine (75 microg clonidine combined with 0.125% bupivacaine)
Number of subjects: 41

Group type: COMPARATOR
Intervention: bupivacaine-fentanyl (50 microg fentanyl combined with 0.125% bupivacaine)
Number of subjects: 41

Group type: COMPARATOR
Intervention: bupivacaine-fentanyl
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: bupivacaine-clonidine
Number of subjects: 41
Study: 9170302

Group type: EXPERIMENTAL
Intervention: Actual case description (raters informed of actual abuse status)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pretend case description (raters informed of opposite abuse status)
Number of subjects: 40
Study: 1550043

Group type: EXPERIMENTAL
Intervention: 30% fat diet with 9% saturated fatty acids (Step 1 diet)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Average American diet (AAD)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 30% fat diet with 14% saturated fatty acids (Sat diet)
Number of subjects: 48
Study: 3699241

Group type: EXPERIMENTAL
Intervention: Varidase
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 38
Study: 30150280

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) and intravitreal fasudil (IVF)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 44
Study: 30182732

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (broad spectrum vitamins, minerals, and amino acids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27307358

Group type: EXPERIMENTAL
Intervention: Combined group (IV administration of 15 mg/kg of TXA combined with topical administration of 1 g/100 mL of TXA)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Single IV group (IV administration of 15 mg/kg of TXA)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 150
Study: 25609368

Group type: EXPERIMENTAL
Intervention: Real needle acupuncture
Number of subjects: 19

Group type: COMPARATOR
Intervention: Park sham needle acupuncture
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy volunteers (16 participants)
Number of subjects: 19
Study: 23761133

Group type: EXPERIMENTAL
Intervention: ASIST training (n = 31)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Resilience Retreat (control, n = 24)
Number of subjects: 55
Study: 20605942

Group type: EXPERIMENTAL
Intervention: Parent follow‐in comments
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Parent follow‐in directives
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Parent expansions of child verbal utterances
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Metrics representing the number of parent utterances following into the child's focus of attention
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Metrics representing the number of parent utterances responding to child verbal communication acts
Number of subjects: 32
Study: 19138971

Group type: EXPERIMENTAL
Intervention: Dietary modification intervention group (reduced total dietary fat intake to 20% of total energy intake, increased fruit and vegetable intake to > or =5 servings/d, and grain products to > or =6 servings/d)
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Comparison group (no specific dietary modification mentioned)
Number of subjects: 48835

Group type: EXPERIMENTAL
Intervention: Dietary modification intervention
Number of subjects: 48835
Study: 16367858

Group type: EXPERIMENTAL
Intervention: Regenerative material applied in test subjects
Number of subjects: 122

Group type: COMPARATOR
Intervention: Omitted regenerative material in controls
Number of subjects: 122
Study: 14687987

Group type: EXPERIMENTAL
Intervention: Fludarabine + prednisone (arm A: 66 patients)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Fludarabine + prednisone + IFN-alpha (arm B: 67 patients)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: IFN-alpha maintenance therapy (41 patients)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Clinical observation (37 patients)
Number of subjects: 133
Study: 11151453

Group type: EXPERIMENTAL
Intervention: Trastuzumab as a single agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab in combination with chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trastuzumab (combined with anthracyclines)
Number of subjects: 0
Study: 8830943

Group type: EXPERIMENTAL
Intervention: Toluene (100 ppm)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 6